AmorChem partners in new treatment for Friedreich’s Ataxia
AmorChem has entered into a collaboration on a project focused on finding a new treatment for patients suffering from the disease Friedreich’s Ataxia. The project was initiated by Jacques P. Tremblay, professor at the Université Laval Faculty of Medicine and researcher at the CHU de Québec Research Centre, and his team. The project has been supported by technology development and commercialization firm SOVAR. AmorChem, a Montréal-based life sciences fund managed by venture capital firm GeneChem, has so far this year announced a total of seven new R&D-stage investments and partnerships.
6 August 2014•5 mins read
